Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine vs Fludarabine/Cytarabine in Elderly AML
NCT02319135Phase 3Completed
- Sponsor
- Fundación PETHEMA
- Start
- Oct 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Overall Survival at 4 years. Started Oct 2014; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02319135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319135.